Tratamentul keratoconului – crosslinking UV™–X
Close
Articolul precedent
Articolul urmator
327 3
Ultima descărcare din IBN:
2023-09-16 17:42
SM ISO690:2012
TONCOGLAZ, Cristina, TUMURUC, Irina. Tratamentul keratoconului – crosslinking UV™–X. In: Culegere de rezumate științifice ale studenților, rezidenților și tinerilor cercetători, 21 iunie 2015, Chișinău1. Chișinău, Republica Moldova: CEP ”Medicina”, 2015, p. 130. ISBN 978-9975-3168-4-2.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Culegere de rezumate științifice ale studenților, rezidenților și tinerilor cercetători 2015
Conferința "-"
Chișinău1, Moldova, 21 iunie 2015

Tratamentul keratoconului – crosslinking UV™–X

The treatment of keratoconus – crosslinking UV™–X


Pag. 130-130

Toncoglaz Cristina, Tumuruc Irina
 
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“
 
 
Disponibil în IBN: 16 iulie 2021


Rezumat

Introducere. Keratoconul reprezintă ectazia bilaterală, conică, neinflamatorie a corneei. Corneal Collagen Cross linking with riboflavin (UVTM–X) consolidează proprietatea biomecanică intrinsecă a corneei utilizând razele ultraviolete A (UVA) şi riboflavină 0,1%. Scopul lucrării. Evaluarea importanței clinice a procedurii crosslinking UVTM–X în stoparea progresiei keratoconului. Material şi metode. Studiu clinic prospectiv, care a inclus 82 ochi cu keratocon moderat sau rapid progresiv (K: 48 – 72 D). S-au efectuat două tehnici de tratament: 42 ochi – UVTM–X epi-off şi 40 ochi – UVTM–X epi-on. UVTM–X epi-off constă în abraziunea centrală a corneei, aplicarea soluției riboflavină 0,1% şi expunerea la UVA (365 nm, 3 mW/cm2), la distanța de 5 cm, 30 minute. UVTM– X epi-on: fără dezepitelizarea corneei, instilarea soluției riboflavină balansată pentru 20 minute şi expunerea la UVA (365 nm, 9mW/cm2), 10 minute. Examinarea postoperatorie a fost efectuată la intervale de 1 zi, 1 săptămână, 1, 3, 6 luni, incluzând: acuitatea vizuală, biomicroscopia, topografia corneei, pahimetria, refractometria, keratometria. Rezultate. La toți ochii tratați a fost oprită progresia keratoconului. Acuitatea vizuală s-a îmbunătățit uşor la 42 ochi (51,2%). Priopritatea utilizării UVTM–X epi-on constă în lipsa sindromului dolor şi recuperarea postoperatorie rapidă. Concluzii. Crosslinking – UV™–X a devenit o nouă modalitate de a stopa progresia keratoconului.

Introduction. Keratoconus is a bilateral noninflammatory conelike ectasia of the cornea. Corneal Collagen Cross linking with riboflavin (UVTM–X) strengthens the intrinsic biomechanical property of the cornea using ultraviolet A (UVA) and riboflavin 0,1%. Objective of the study. To evaluate the clinical usefulness of crosslinking – UVTM for stopping the progression of keratoconus. Material and methods. Clinical prospective study, that included 82 eyes with moderate or advanced progressive keratoconus (K: 48 – 72 D). Two techniques of treatment were performed: in 42 eyes ‒ UVTM-X epi-off and in 40 eyes – UVTM‒X epi-on. The first is accomplished with central corneal abrasion, riboflavin drops and exposure to UVA (365 nm, 3 mW/cm2) at 5 cm distance for 30 minutes. UVTM–X epi-on is performed without desepitalization of the cornea with balanced solution of riboflavin instilled for 20 minutes and UVA exposure (365 nm, 9 mW/cm2) for 10 minutes. Postoperative examinations were carried over the course of 1 day,1 week, 1, 3 and 6 months, including visual acuity, biomicroscopy, corneal topography, pachymetry, refractometry, keratometry. Results. In all treated eyes, the progression of keratoconus was stopped. In 42 eyes (51.2%) visual acuity was improved. The priority of UVTM–X epi-on tehnique results in absence of pain syndrome and fast postoperative recovery. Conclusions. Crosslinking – UVTM‒X is a way for stopping the progression of keratoconus.

Cuvinte-cheie
keratocon, UltraViolet Crosslinking, UVTM–X epi-on, UVTM–X epi-off,

keratoconus, UltraViolet Crosslinking, UVTM–X epi-on, UVTM–X epi-off

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-135544</cfResPublId>
<cfResPublDate>2015</cfResPublDate>
<cfStartPage>130</cfStartPage>
<cfISBN>978-9975-3168-4-2</cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/135544</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Tratamentul keratoconului &ndash; crosslinking UV&trade;&ndash;X</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>keratocon; UltraViolet Crosslinking; UVTM–X epi-on; UVTM–X epi-off; keratoconus; UltraViolet Crosslinking; UVTM–X epi-on; UVTM–X epi-off</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere. Keratoconul reprezintă ectazia bilaterală, conică, neinflamatorie a corneei. Corneal Collagen Cross linking with riboflavin (UVTM&ndash;X) consolidează proprietatea biomecanică intrinsecă a corneei utiliz&acirc;nd razele ultraviolete A (UVA) şi riboflavină 0,1%. Scopul lucrării. Evaluarea importanței clinice a procedurii crosslinking UVTM&ndash;X &icirc;n stoparea progresiei keratoconului. Material şi metode. Studiu clinic prospectiv, care a inclus 82 ochi cu keratocon moderat sau rapid progresiv (K: 48 &ndash; 72 D). S-au efectuat două tehnici de tratament: 42 ochi &ndash; UVTM&ndash;X epi-off şi 40 ochi &ndash; UVTM&ndash;X epi-on. UVTM&ndash;X epi-off constă &icirc;n abraziunea centrală a corneei, aplicarea soluției riboflavină 0,1% şi expunerea la UVA (365 nm, 3 mW/cm2), la distanța de 5 cm, 30 minute. UVTM&ndash; X epi-on: fără dezepitelizarea corneei, instilarea soluției riboflavină balansată pentru 20 minute şi expunerea la UVA (365 nm, 9mW/cm2), 10 minute. Examinarea postoperatorie a fost efectuată la intervale de 1 zi, 1 săptăm&acirc;nă, 1, 3, 6 luni, incluz&acirc;nd: acuitatea vizuală, biomicroscopia, topografia corneei, pahimetria, refractometria, keratometria. Rezultate. La toți ochii tratați a fost oprită progresia keratoconului. Acuitatea vizuală s-a &icirc;mbunătățit uşor la 42 ochi (51,2%). Priopritatea utilizării UVTM&ndash;X epi-on constă &icirc;n lipsa sindromului dolor şi recuperarea postoperatorie rapidă. Concluzii. Crosslinking &ndash; UV&trade;&ndash;X a devenit o nouă modalitate de a stopa progresia keratoconului.</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction. Keratoconus is a bilateral noninflammatory conelike ectasia of the cornea. Corneal Collagen Cross linking with riboflavin (UVTM&ndash;X) strengthens the intrinsic biomechanical property of the cornea using ultraviolet A (UVA) and riboflavin 0,1%. Objective of the study. To evaluate the clinical usefulness of crosslinking &ndash; UVTM for stopping the progression of keratoconus. Material and methods. Clinical prospective study, that included 82 eyes with moderate or advanced progressive keratoconus (K: 48 &ndash; 72 D). Two techniques of treatment were performed: in 42 eyes ‒ UVTM-X epi-off and in 40 eyes &ndash; UVTM‒X epi-on. The first is accomplished with central corneal abrasion, riboflavin drops and exposure to UVA (365 nm, 3 mW/cm2) at 5 cm distance for 30 minutes. UVTM&ndash;X epi-on is performed without desepitalization of the cornea with balanced solution of riboflavin instilled for 20 minutes and UVA exposure (365 nm, 9 mW/cm2) for 10 minutes. Postoperative examinations were carried over the course of 1 day,1 week, 1, 3 and 6 months, including visual acuity, biomicroscopy, corneal topography, pachymetry, refractometry, keratometry. Results. In all treated eyes, the progression of keratoconus was stopped. In 42 eyes (51.2%) visual acuity was improved. The priority of UVTM&ndash;X epi-on tehnique results in absence of pain syndrome and fast postoperative recovery. Conclusions. Crosslinking &ndash; UVTM‒X is a way for stopping the progression of keratoconus.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-91422</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-91319</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-91422</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-91422-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Toncoglaz</cfFamilyNames>
<cfFirstNames>Cristina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-91319</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-91319-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Tumuruc</cfFamilyNames>
<cfFirstNames>Irina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>